Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1970 Jan;1(1):128–134. doi: 10.1128/iai.1.1.128-134.1970

In Vivo Susceptibility of Cryptococcus neoformans to Hamycin, Amphotericin B, and 5-Fluorocytosine 1

Smith Shadomy a, H Jean Shadomy a, J P Utz a
PMCID: PMC415864  PMID: 16557685

Abstract

Previous investigations have shown that hamycin is 5 to 10 times more active in vitro than amphotericin B against Cryptococcus neoformans, whereas 5-fluorocytosine is approximately 15 times less active. Present studies are concerned with a comparison of these drugs in vivo. Three strains of C. neoformans which varied in both their virulence for mice and their susceptibilities to the antifungal agents were studied. Acute experimental infections were established in mice by using inocula containing approximately 4 × 106 cells. The mice were treated by gastric intubation for 28 days; daily dosages of the three drugs ranged from 12.5 to 250 mg/kg. The polyenes were suspended in 5% dimethyl sulfoxide, whereas 5-fluorocytosine was suspended in saline. Amphotericin B was the most effective drug, with almost complete absence of toxic deaths in control mice and increased survival in mice infected with two of the three strains and treated with 25 mg/kg per day or more. 5-Fluorocytosine was nontoxic but provided protection against only one strain. Hamycin was both the least effective and the most toxic compound, providing only slight protection at doses of 12.5 or 25 mg/kg per day and causing toxic deaths in over 50% of uninfected mice at doses above 25 mg/kg per day.

Full text

PDF
128

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BENNETT J. E., WILLIAMS T. W., PIGGOTT W., EMMONS C. W. IN VIVO ACTIVITY OF COLLOIDAL HAMYCIN, AN ANTIFUNGAL ANTIBOTIC. Proc Soc Exp Biol Med. 1964 Oct;117:166–170. doi: 10.3181/00379727-117-29525. [DOI] [PubMed] [Google Scholar]
  2. CAMPBELL C. C., HILL G. B. Beneficial therapeutic effects of solubilized amphotericin B after oral administration in experimental coccidioidomycosis, histoplasmosis, and cryptococcosis in mice. Antibiot Annu. 1959;7:622–630. [PubMed] [Google Scholar]
  3. LOURIA D. B., FEDER N., EMMONS C. W. Amphotericin B in experimental histoplasmosis and Cryptococcosis. Antibiot Annu. 1956:870–877. [PubMed] [Google Scholar]
  4. Shadomy S. In vitro studies with 5-fluorocytosine. Appl Microbiol. 1969 Jun;17(6):871–877. doi: 10.1128/am.17.6.871-877.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Shadomy S., McCay J. A., Schwartz S. I. Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol. 1969 Apr;17(4):497–503. doi: 10.1128/am.17.4.497-503.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Shadomy S., Robertson G. M., Jr, Shadomy H. J., Utz J. P., Gamble E. In vitro and in vivo activity of hamycin against Blastomyces dermatitidis. J Bacteriol. 1969 Feb;97(2):481–487. doi: 10.1128/jb.97.2.481-487.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Shadomy S., Shadomy H. J., McCay J. A., Utz J. P. In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda) 1968;8:452–460. [PubMed] [Google Scholar]
  8. Utz J. P., Shadomy H. J., Shadomy S. Clinical and laboratory studies of a new micronized preparation of hamycin in systemic mycoses in man. Antimicrob Agents Chemother (Bethesda) 1967;7:113–117. doi: 10.1128/AAC.7.1.113. [DOI] [PubMed] [Google Scholar]
  9. Utz J. P., Tynes B. S., Shadomy H. J., Duma R. J., Kannan M. M., Mason K. N. 5-Fluorocytosine in human cryptococcosis. Antimicrob Agents Chemother (Bethesda) 1968;8:344–346. doi: 10.1128/AAC.8.3.344. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES